msa

Investment Landscape: Multiple System Atrophy

Overview

Multiple System Atrophy (MSA) is a rare, rapidly progressive atypical parkinsonism characterized by autonomic dysfunction, parkinsonism (MSA-P subtype), and cerebellar ataxia (MSA-C subtype)[@krismer2023]. MSA is classified as an alpha-synucleinopathy, sharing pathological features with [Parkinson's Disease](/diseases/parkinsons-disease) but with distinct oligodendrocyte pathology. The rapidly progressive nature (median survival 6-9 years) makes MSA one of the most aggressive neurodegenerative disorders and an area of significant unmet need[@jeciso2023].

Last updated: 2026-03-29 12:05 PT

Clinical Trial Pipeline

Active and recent MSA clinical trials:

| NCT Number | Agent/Sponsor | Mechanism | Phase | Status | Notes |
|------------|--------------|-----------|-------|--------|-------|
| [NCT05224379](https://clinicaltrials.gov/study/NCT05224379) | BLD-2660 | Anti-inflammatory / neuroprotective | Phase 2 | Completed | Novel neuroprotective compound |
| [NCT04449485](https://clinicaltrials.gov/study/NCT04449485) | Cinumercept | Immunotherapy | Phase 1/2 | Completed | Monoclonal antibody targeting alpha-synuclein |
| [NCT05121012](https://clinicaltrials.gov/study/NCT05121012) | Synaptic loss study | Biomarker | Observational | Active | CSF synaptic biomarkers in MSA |
| [NCT04706234](https://clinicaltrials.gov/study/NCT04706234) | FEEMSA | Device | Phase 2 | Active | Laryngopharyngeal dysfunction in PSP/MSA |

Trial Landscape Analysis

Investment Landscape: Multiple System Atrophy

Overview

Multiple System Atrophy (MSA) is a rare, rapidly progressive atypical parkinsonism characterized by autonomic dysfunction, parkinsonism (MSA-P subtype), and cerebellar ataxia (MSA-C subtype)[@krismer2023]. MSA is classified as an alpha-synucleinopathy, sharing pathological features with [Parkinson's Disease](/diseases/parkinsons-disease) but with distinct oligodendrocyte pathology. The rapidly progressive nature (median survival 6-9 years) makes MSA one of the most aggressive neurodegenerative disorders and an area of significant unmet need[@jeciso2023].

Last updated: 2026-03-29 12:05 PT

Clinical Trial Pipeline

Active and recent MSA clinical trials:

| NCT Number | Agent/Sponsor | Mechanism | Phase | Status | Notes |
|------------|--------------|-----------|-------|--------|-------|
| [NCT05224379](https://clinicaltrials.gov/study/NCT05224379) | BLD-2660 | Anti-inflammatory / neuroprotective | Phase 2 | Completed | Novel neuroprotective compound |
| [NCT04449485](https://clinicaltrials.gov/study/NCT04449485) | Cinumercept | Immunotherapy | Phase 1/2 | Completed | Monoclonal antibody targeting alpha-synuclein |
| [NCT05121012](https://clinicaltrials.gov/study/NCT05121012) | Synaptic loss study | Biomarker | Observational | Active | CSF synaptic biomarkers in MSA |
| [NCT04706234](https://clinicaltrials.gov/study/NCT04706234) | FEEMSA | Device | Phase 2 | Active | Laryngopharyngeal dysfunction in PSP/MSA |

Trial Landscape Analysis

MSA has approximately 6-8 registered clinical trials total (both active and completed), reflecting the rarity of the disease. Key features:

• Phase 1/2 focus: Majority of trials in early phases, limited Phase 3 activity
• Synuclein targeting: Multiple programs targeting alpha-synuclein aggregation or propagation
• Neuroprotective approaches: Broad-spectrum neuroprotection given rapid progression
• Symptomatic trials: Autonomic dysfunction management (orthostatic hypotension, urinary dysfunction)

Investment Context

MSA represents one of the most challenging and underserved indications in neurodegeneration:

Key Investment Themes

• Alpha-synuclein modulation: Programs from biotech companies targeting alpha-synuclein aggregation
• Neuroprotection: Preserving autonomic and motor neurons given rapid progression
• Autonomic dysfunction: Orthostatic hypotension, bladder/bowel dysfunction primary causes of morbidity
• Myelin protection: Oligodendrocyte dysfunction is central to MSA pathology
• Biomarker development: Neurofilament light chain (NfL), alpha-synuclein seed amplification assays

Investment Barriers

MSA investment faces unique challenges:

• Rapid progression: Shorter window for intervention than PD or AD
• Diagnostic delay: Average 3-5 years from symptom onset to diagnosis
• Heterogeneity: MSA-P vs MSA-C phenotypes complicate trial design
• Limited patient registries: Challenge in recruiting for rare disease trials
• No established surrogate endpoints: Autonomic testing less validated than motor scores

Emerging Investment Areas

• Alpha-synuclein antibodies: Active programs from Biogen, Roche, and smaller biotech
• Small molecule aggregation inhibitors: Oral compounds targeting alpha-synuclein misfolding
• Gene therapy: AAV-based delivery of neuroprotective factors (GDNF, BDNF)
• Repurposed drugs: GLP-1 agonists, methylprednisolone, minocycline being evaluated

Therapeutic Pipeline

| Company | Program | Mechanism | Stage | Notes |
|---------|---------|-----------|-------|-------|
| Bionure/Pharma | BLD-2660 | Neuroprotective | Phase 2 | Completed, positive signal |
| Cinumercept | CIN-101 | Anti-alpha-synuclein antibody | Phase 1/2 | Completed |
| Roche | Anti-alpha-synuclein antibody | IgECT | Phase 1 | Cross-indication |
| Takeda | Epidermal growth factor | Myelin repair | Preclinical | Japan-based program |
| Novo Nordisk | GLP-1 agonists | Metabolic modulation | Phase 2 | Repurposed from diabetes |
| UCB | Neuroprotective peptides | Neuroprotection | Phase 1 | European program |

Funding Landscape

Research Grants and Foundations

• MSA Coalition: Leading patient advocacy organization, funding mechanism and biomarker research
• MSA Trust (UK): Funding clinical research and patient registry development
• NIH: R01/R21 grants for MSA mechanism research, approximately $8-12M annually
• Michael J. Fox Foundation: Co-funding alpha-synuclein biomarker and therapy programs
• European MSA Study Group (EMSA-SG): Academic network facilitating clinical trials

Venture Capital Activity

MSA-specific VC investment remains limited due to:

• Small patient population (~50,000 in US, ~100,000 in EU)
• High risk of rapid trial failure
• However, programs targeting alpha-synuclein in PD often include MSA as secondary indication

Pharma Partnerships

• Roche/Genentech: Anti-alpha-synuclein antibody program includes MSA cohort
• Novartis: Autonomic dysfunction program extends to MSA
• AstraZeneca: Neuroprotection partnerships with academic MSA groups

Research Investment Priorities

Diagnostic Biomarkers

Investment priority in:

• Alpha-synuclein seed amplification assays (SAA): CSF-based detection of pathological alpha-synuclein
• Neurofilament light chain (NfL): Blood-based marker of neuronal damage
• MRI markers: "Hot cross bun" sign, putaminal atrophy, brainstem volume
• Autonomic testing: Heart rate variability, urinary biomarkers

Therapeutic Targets

| Target Category | Investment Level | Rationale |
|----------------|-----------------|-----------|
| Alpha-synuclein aggregation | High | Central pathology |
| Oligodendrocyte support | Medium | Unique to MSA |
| Autonomic dysfunction | Medium | Primary cause of mortality |
| Neuroinflammation | Medium | TAM receptor pathways |
| Mitochondrial dysfunction | Low-Medium | Prominent in MSA |

Investment Outlook

Near-Term (1-3 Years)

Alpha-synuclein antibody readouts from PD programs that may inform MSA strategy. Biomarker validation studies. Continued Phase 1/2 activity. Autonomic dysfunction device programs advancing.

Medium-Term (3-5 Years)

First MSA-specific Phase 3 trials expected. Blood-based biomarkers enabling faster enrollment. Possible repurposing of anti-alpha-synuclein antibodies from PD. Gene therapy programs entering clinical stage.

Long-Term (5-10 Years)

Disease-modifying therapies with validated mechanisms. Prevention trials in prodromal MSA. Personalized approach based on MSA-P vs MSA-C subtype. First disease-modifying therapy approval could unlock significant investment.

Related Pages

• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Dysfunction](/mechanisms/autonomic-dysfunction-neurodegeneration)
• [Clinical Trials: MSA](/clinical-trials/bld-2660-msa-nct05224379)

See Also

• [Parkinson's Disease Investment](/investment/pd-pipeline)
• [Alpha-Synuclein Therapeutics](/investment/alpha-synuclein)
• [Neuroimmune Investment](/investment/neuroinflammation-investment)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving msa discovered through SciDEX knowledge graph analysis: